The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Open accessAbstract
The elucidation of breast cancer subgroups and their molecular drivers requires integrated views of the genome and transcriptome from representative numbers of patients. We present an integrated analysis of copy number and gene expression in a discovery and validation set of 997 and 995 primary breast tumours, respectively, with long-term clinical follow-up. Inherited variants (copy number variants and single nucleotide polymorphisms) and acquired somatic copy number aberrations (CNAs) were associated with expression in ~40% of genes, with the landscape dominated by cis- and trans-acting CNAs. By delineating expression outlier genes driven in cis by CNAs, we identified putative cancer genes, including deletions in PPP2R2A, MTAP and MAP2K4. Unsupervised analysis of paired DNA–RNA profiles revealed novel subgroups with distinct clinical outcomes, which reproduced in the validation cohort. These include a high-risk, oestrogen-receptor-positive 11q13/14 cis-acting subgroup and a favourable prognosis subgroup devoid of CNAs. Trans-acting aberration hotspots were found to modulate subgroup-specific gene networks, including a TCR deletion-mediated adaptive immune response in the ‘CNA-devoid’ subgroup and a basal-specific chromosome 5 deletion-associated mitotic network. Our results provide a novel molecular stratification of the breast cancer population, derived from the impact of somatic CNAs on the transcriptome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Currently, numerous research efforts are focused on utilizing genetic data and artificial intelligence algorithms to develop diagnostic models to enhance the clinical efficiency and accuracy of breast cancer diagnosis [109,110,111].”
From A Comprehensive Review on Synergy of Multi-Modal Data and AI Technologies in Medical Diagnosis (2024) · cites this paper as [111]
In the citing paper
“This framework was also employed for a landmark study which used genomic and transcriptomic data from 2,000 breast tumours and discovered novel subgroups amongst them (Curtis et al., 2012).”
From Using machine learning approaches for multi-omics data analysis: A review (2021) · cites this paper as Curtis et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Self-citationNishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239
Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506
Self-citationSupervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S. C. Y., Voduc, D. K., Vickery, T. L., Davies, S. R., Fauron, C. M. ‐., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,818
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Ki67 expression in breast cancer
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Diagnosis of multiple cancer types by shrunken centroids of gene expression
Tibshirani, R. J., Hastie, T. J., Narasimhan, B., & Chu, G. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082099299 · Cited by 2,931
Tumor-Infiltrating CD8+Lymphocytes Predict Clinical Outcome in Breast Cancer
Mahmoud, S., Paish, E. C., Powe, D. G., Macmillan, R. D., Grainge, M. J., Lee, A. H. S., Ellis, I. O., & Green, A. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5037 · Cited by 1,411
Self-citationGenomic and transcriptional aberrations linked to breast cancer pathophysiologies
Chin, K., DeVries, S., Fridlyand, J., Spellman, P. T., Roydasgupta, R., Kuo, W.-L., Lapuk, A. V., Neve, R. M., Qian, Z., Ryder, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.009 · Cited by 1,309
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Jones, S., Wang, T., Shih, I., Mao, T., Nakayama, K., Roden, R. B. S., Glas, R., Slamon, D. J., Diaz, L. A., Vogelstein, B., et al. (2010) · Science · doi:10.1126/science.1196333 · Cited by 1,218
Flagged first, then by citations
Cited by
Sorted by citations
Items 1,001–1,028 of 1,028
Zhang, G., Wang, Y., Chen, B., Guo, L., Cao, L., Ren, C., Wen, L., Li, K., Jia, M., Li, C., et al. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.04.23 · Cited by 66
Alanazi, M. S., Parine, N. R., Shaik, J. P., Alabdulkarim, H. A., Ajaj, S. A., & Khan, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059555 · Cited by 69
Hypoxic regulation of RIOK3 is a major mechanism for cancer cell invasion and metastasis
Singleton, D. C., Rouhi, P., Zois, C. E., Haider, S., Li, J.-L., Kessler, B. M., Cao, Y., & Harris, A. L. (2015) · Oncogene · doi:10.1038/onc.2014.396 · Cited by 52
Kumegawa, K., Takahashi, Y., Saeki, S., Yang, L., Nakadai, T., Osako, T., Mori, S., Noda, T., Ohno, S., Ueno, T., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00438-6 · Cited by 45
Auslander, N., Yizhak, K., Weinstock, A., Budhu, A., Tang, W., Wang, X. W., Ambs, S., & Ruppin, E. (2016) · Scientific Reports · doi:10.1038/srep29662 · Cited by 50
Involvement of NRF2 in Breast Cancer and Possible Therapeutical Role of Polyphenols and Melatonin
Tascioglu Aliyev, A., Panieri, E., Stepanić, V., Gurer-Orhan, H., & Saso, L. (2021) · Molecules · doi:10.3390/molecules26071853 · Cited by 50
Identification of synergistic drug combinations using breast cancer patient-derived xenografts
Turner, T. H., Alzubi, M. A., & Harrell, J. C. (2020) · Scientific Reports · doi:10.1038/s41598-020-58438-0 · Cited by 50
Loss of protein phosphatase 2A regulatory subunit B56δ promotes spontaneous tumorigenesis in vivo
Lambrecht, C., Libbrecht, L., Sagaert, X., Pauwels, P., Hoorne, Y., Crowther, J., Louis, J. V., Sents, W., Sablina, A., & Janssens, V (2018) · Oncogene · doi:10.1038/onc.2017.350 · Cited by 50
Telomere fusion threshold identifies a poor prognostic subset of breast cancer patients
Simpson, K., Jones, R. E., Grimstead, J. W., Hills, R., Pepper, C., & Baird, D. M. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.02.003 · Cited by 46
Goldsworthy, M., Bai, Y., Li, C.-M., Ge, H., Lamas, E., Hilton, H., Esapa, C. T., Baker, D., Baron, W., Juan, T., et al. (2016) · Diabetes · doi:10.2337/db15-1276 · Cited by 35
EPRS is a critical regulator of cell proliferation and estrogen signaling in ER+ breast cancer
Katsyv, I., Wang, M., Song, W. M., Zhou, X., Zhao, Y., Park, S., Zhu, J., Zhang, B., & Irie, H. Y. (2016) · Oncotarget · doi:10.18632/oncotarget.11870 · Cited by 47
Cutano, V., Di Giorgio, E., Minisini, M., Picco, R., Dalla, E., & Brancolini, C. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12503 · Cited by 44
PP2A Inactivation Mediated by PPP2R4 Haploinsufficiency Promotes Cancer Development
Sents, W., Meeusen, B., Kalev, P., Radaelli, E., Sagaert, X., Miermans, E., Haesen, D., Lambrecht, C., Dewerchin, M., Carmeliet, P., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2911 · Cited by 42
Salemi, M., Mogavero, M. P., Lanza, G., Mongioì, L. M., Calogero, A. E., & Ferri, R. (2022) · Cells · doi:10.3390/cells11121930 · Cited by 39
SimplePPT: A Simple Principal Tree Algorithm
Mao, Q., Yang, L., Wang, L., Goodison, S., & Sun, Y. (2015) · Proceedings of the 2015 SIAM International Conference on Data Mining · doi:10.1137/1.9781611974010.89 · Cited by 33
Williams, M. J., Oliphant, M. U. J., Au, V., Liu, C., Baril, C., O’Flanagan, C., Lai, D., Beatty, S., Van Vliet, M., Yiu, J. C., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01988-0 · Cited by 34
Self-citationElevation of SIPL1 (SHARPIN) increases breast cancer risk
De Melo, J., & Tang, D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0127546 · Cited by 33
Goel, I., Bhaskar, Y., Kumar, N., Singh, S., Amanullah, M., Dhar, R., & Karmakar, S. (2025) · Frontiers in Digital Health · doi:10.3389/fdgth.2025.1550407 · Cited by 31
Functional importance of PP2A regulatory subunit loss in breast cancer
Watt, L. F., Panicker, N., Mannan, A., Copeland, B., Kahl, R. G. S., Dun, M. D., Young, B., Roselli, S., & Verrills, N. M. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4403-5 · Cited by 29
Yang, Y., Yang, H. H., Tang, B., Wu, A. M. L., Flanders, K. C., Moshkovich, N., Weinberg, D. S., Welsh, M. A., Weng, J., Ochoa, H. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2370 · Cited by 29
Wang, Y. K., Print, C. G., & Crampin, E. J. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-102 · Cited by 28
Detecting molecular subtypes from multi-omics datasets using SUMO
Sienkiewicz, K., Chen, J., Chatrath, A., Lawson, J. T., Sheffield, N. C., Zhang, L., & Ratan, A. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2021.100152 · Cited by 18
“We also downloaded two breast cancer datasets from METABRIC.”
InfluentialDevelopment of NR0B2 as a therapeutic target for the re-education of tumor associated myeloid cells
Vidana Gamage, H. E., Albright, S. T., Smith, A. J., Farmer, R., Shahoei, S. H., Wang, Y., Fink, E. C., Jacquin, E., Weisser, E., Bautista, R. O., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217086 · Cited by 13
Deep multi-modal fusion network with gated unit for breast cancer survival prediction
Yuan, H., & Xu, H. (2024) · Computer Methods in Biomechanics and Biomedical Engineering · doi:10.1080/10255842.2023.2211188 · Cited by 10
The exostosin glycosyltransferase 1/STAT3 axis is a driver of breast cancer aggressiveness
Solaimuthu, B., Khatib, A., Tanna, M., Karmi, A., Hayashi, A., Abu Rmaileh, A., Lichtenstein, M., Takoe, S., Jolly, M. K., & Shaul, Y. D. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2316733121 · Cited by 8
Targeting PP2A in cancer: an underrated option
Sarais, F., Krempien, F., Koehn, C., Brewing, L., Classen, C. F., Walter, M., & Shokraie, O. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03560-y · Cited by 8
SetQuence & SetOmic: Deep Set Transformer-based Representations of Cancer Multi-Omics
Jurenaite, N., León-Periñán, D., Donath, V., Torge, S., & Jäkel, R. (2022) · 2022 IEEE Conference on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB) · doi:10.1109/cibcb55180.2022.9863058 · Cited by 5
Research progress of T cells in cholangiocarcinoma
Wang, Z., Dai, Y., Zhou, Y., Wang, Y., Chen, P., Li, Y., Zhang, Y., Wang, X., Hu, Y., Li, H., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1453344 · Cited by 2
Metadata
- Authors
- METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., Yuan, Y., Gräf, S., Ha, G., Haffari, G., Bashashati, A., Russell, R., McKinney, S., Langerød, A., Green, A., Provenzano, E., Wishart, G., Pinder, S., Watson, P., Markowetz, F., Murphy, L., Ellis, I., Purushotham, A., Børresen-Dale, A.-L., Brenton, J. D., Tavaré, S., Caldas, C., & Aparicio, S.
- Affiliations
- University of Cambridge (GB)
- University of British Columbia (CA)
- Oslo University Hospital (NO)
- University of Nottingham (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- King's College London (GB)
- University of Southern California (US)
- Corresponding author
- Caldas, Carlos
- Aparicio, Samuel
- ORCID
- Curtis, Christina
- Shah, Sohrab P.
- Chin, Suet-Feung
- Turashvili, Gulisa
- Rueda, Oscar M.
- Dunning, Mark J.
- Speed, Doug
- Lynch, Andy G.
- Samarajiwa, Shamith
- Yuan, Yinyin
- Gräf, Stefan
- Ha, Gavin
- Haffari, Gholamreza
- Bashashati, Ali
- Green, Andrew
- Provenzano, Elena
- Wishart, Gordon
- Pinder, Sarah
- Watson, Peter
- Markowetz, Florian
- Murphy, Leigh
- Ellis, Ian
- Purushotham, Arnie
- Brenton, James D.
- Tavaré, Simon
- Caldas, Carlos
- Aparicio, Samuel
- Venue
- Nature
- Published
- 2012-04-18
- Volume
- 486
- Issue
- 7403
- Pages
- 346-352
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3440846
- OpenAlex
- W2005895632
- Cited by
- 6,097
- References
- 32
- Citations by year
- 2026: 341 · 2025: 411 · 2024: 458 · 2023: 497 · 2022: 496 · 2021: 615 · 2020: 533 · 2019: 449 · 2018: 426 · 2017: 361 · 2016: 373 · 2015: 378 · 2014: 339 · 2013: 291 · 2012: 119
- FWCI
- 119.67
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- University of Southern California
- Michael Smith Health Research BC
- Cancer Research UK (A7199, 15601, 19556)
- National Institute for Health and Care Research (ACF-2012-14-006, NF-SI-0611-10154)
- University of Cambridge
- King's College London
- National Institutes of Health
- BC Cancer Agency
- NIHR Cambridge Biomedical Research Centre
- National Human Genome Research Institute (P50-HG02790, P50HG002790)
- Division of Mathematical Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
- Keywords
- breast cancer, copy number alterations, somatic copy number alterations, gene expression, single nucleotide polymorphisms, PPP2R2A, MTAP, MAP2K4, estrogen receptor-positive breast cancer, adaptive immune response, basal-like breast cancer, chromosome 5 deletion, molecular stratification, prognosis
- MeSH terms
- Breast Neoplasms, Female, Humans, Prognosis, Genome, Human, Gene Expression Regulation, Neoplastic, Treatment Outcome, Polymorphism, Single Nucleotide, Gene Expression Profiling, Genomics, MAP Kinase Kinase 4, Genes, Neoplasm, Kaplan-Meier Estimate, Gene Regulatory Networks, Protein Phosphatase 2, DNA Copy Number Variations
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
